MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
MESOBLAST LTD
Financials through fiscal 2025, year ended Jun 30, 2025Last filing: 20-F on Aug 27, 2026
$11.95−1.33 (-10.02%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Mesoblast statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Mesoblast | Industry median |
|---|---|---|
| Market Cap | $15.50B | $197.05M |
| Enterprise Value | $15.56B | $106.56M |
| PS Ratio | 901.12 | 3.93 |
Enterprise value
| Measure | Mesoblast | Industry median |
|---|---|---|
| EV / Sales | 904.82 | 2.69 |
Income (trailing twelve months)
| Measure | Mesoblast | Industry median |
|---|---|---|
| Revenue | $17.20M | $57.94M |
| Gross Profit | $12.07M | $90.47M |
| Pretax Income | -$101.81M | -$14.45M |
| Net Income | -$102.14M | -$22.46M |
| EBITDA | -$72.44M | -$16.91M |
| EPS (Diluted) | -$0.08 | -$0.83 |
Margins
| Measure | Mesoblast | Industry median |
|---|---|---|
| Gross Margin | 70.2% | 52.3% |
| Pretax Margin | -592.0% | -13.0% |
| Profit Margin | -593.9% | -39.2% |
| EBITDA Margin | -421.2% | -31.3% |
| FCF Margin | -294.4% | -8.85% |
Returns
| Measure | Mesoblast | Industry median |
|---|---|---|
| Return on Assets (ROA) | -14.2% | -41.0% |
Growth
| Measure | Mesoblast | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 191.4% | 6.01% |
| Revenue Growth (3Y CAGR) | 19.0% | 2.25% |
| Revenue Growth (5Y CAGR) | -11.8% | 6.42% |
Balance sheet
| Measure | Mesoblast | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $129.98M | $62.42M |
| Total Debt | $193.61M | $120.13M |
| Net Cash (Debt) | -$63.63M | $15.68M |
| Net Cash Per Share | -$0.05 | $0.65 |
| Working Capital | $74.41M | $75.77M |
Financial position
| Measure | Mesoblast | Industry median |
|---|---|---|
| Current Ratio | 1.58 | 3.30 |
| Quick Ratio | 1.35 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Mesoblast | Industry median |
|---|---|---|
| Operating Cash Flow | -$49.95M | -$12.35M |
| Capital Expenditures | -$680.00K | -$1.06M |
| Free Cash Flow | -$50.63M | -$20.28M |
| FCF Per Share | -$0.04 | -$0.41 |
Efficiency
| Measure | Mesoblast | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.38 |
| Inventory Turnover | 0.22 | 2.67 |
| Revenue Per Employee | $159.24K | $398.96K |
| Profits Per Employee | -$945.76K | -$732.08K |
| Employee Count | 108 | 73 |
Dividends and yields
| Measure | Mesoblast | Industry median |
|---|---|---|
| Earnings Yield | -0.66% | -21.2% |
| FCF Yield | -0.33% | -7.64% |
| Buyback Yield | -1.04% | -0.58% |
| Shareholder Yield | -1.04% | 0.00% |
Shares
| Measure | Mesoblast | Industry median |
|---|---|---|
| Shares Outstanding | 1,296,860,000 | 59,128,900 |
| Shares Change (YoY) | 22.4% | 11.1% |
| Float | 813,647,000 | 48,744,500 |
| Shares Held by Insiders | 37.3% | 11.8% |
| Shares Held by Institutions | 0.30% | 59.4% |
Taxes
| Measure | Mesoblast | Industry median |
|---|---|---|
| Income Tax | $330.00K | $91.50K |
Scores
| Measure | Mesoblast | Industry median |
|---|---|---|
| Altman Z-Score | 43.04 | 0.10 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -1.48 | -2.62 |
Calculated by StockData from Mesoblast's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.